{ "schemaVersion": "1.0", "item": { "slug": "longevity-assistant", "name": "Longevity Assistant", "source": "tencent", "type": "skill", "category": "开发工具", "sourceUrl": "https://clawhub.ai/lofimichael/longevity-assistant", "canonicalUrl": "https://clawhub.ai/lofimichael/longevity-assistant", "targetPlatform": "OpenClaw" }, "install": { "downloadMode": "redirect", "downloadUrl": "/downloads/longevity-assistant", "sourceDownloadUrl": "https://wry-manatee-359.convex.site/api/v1/download?slug=longevity-assistant", "sourcePlatform": "tencent", "targetPlatform": "OpenClaw", "installMethod": "Manual import", "extraction": "Extract archive", "prerequisites": [ "OpenClaw" ], "packageFormat": "ZIP package", "includedAssets": [ "SKILL.md" ], "primaryDoc": "SKILL.md", "quickSetup": [ "Download the package from Yavira.", "Extract the archive and review SKILL.md first.", "Import or place the package into your OpenClaw setup." ], "agentAssist": { "summary": "Hand the extracted package to your coding agent with a concrete install brief instead of figuring it out manually.", "steps": [ "Download the package from Yavira.", "Extract it into a folder your agent can access.", "Paste one of the prompts below and point your agent at the extracted folder." ], "prompts": [ { "label": "New install", "body": "I downloaded a skill package from Yavira. Read SKILL.md from the extracted folder and install it by following the included instructions. Tell me what you changed and call out any manual steps you could not complete." }, { "label": "Upgrade existing", "body": "I downloaded an updated skill package from Yavira. Read SKILL.md from the extracted folder, compare it with my current installation, and upgrade it while preserving any custom configuration unless the package docs explicitly say otherwise. Summarize what changed and any follow-up checks I should run." } ] }, "sourceHealth": { "source": "tencent", "status": "healthy", "reason": "direct_download_ok", "recommendedAction": "download", "checkedAt": "2026-04-30T16:55:25.780Z", "expiresAt": "2026-05-07T16:55:25.780Z", "httpStatus": 200, "finalUrl": "https://wry-manatee-359.convex.site/api/v1/download?slug=network", "contentType": "application/zip", "probeMethod": "head", "details": { "probeUrl": "https://wry-manatee-359.convex.site/api/v1/download?slug=network", "contentDisposition": "attachment; filename=\"network-1.0.0.zip\"", "redirectLocation": null, "bodySnippet": null }, "scope": "source", "summary": "Source download looks usable.", "detail": "Yavira can redirect you to the upstream package for this source.", "primaryActionLabel": "Download for OpenClaw", "primaryActionHref": "/downloads/longevity-assistant" }, "validation": { "installChecklist": [ "Use the Yavira download entry.", "Review SKILL.md after the package is downloaded.", "Confirm the extracted package contains the expected setup assets." ], "postInstallChecks": [ "Confirm the extracted package includes the expected docs or setup files.", "Validate the skill or prompts are available in your target agent workspace.", "Capture any manual follow-up steps the agent could not complete." ] }, "downloadPageUrl": "https://openagent3.xyz/downloads/longevity-assistant", "agentPageUrl": "https://openagent3.xyz/skills/longevity-assistant/agent", "manifestUrl": "https://openagent3.xyz/skills/longevity-assistant/agent.json", "briefUrl": "https://openagent3.xyz/skills/longevity-assistant/agent.md" }, "agentAssist": { "summary": "Hand the extracted package to your coding agent with a concrete install brief instead of figuring it out manually.", "steps": [ "Download the package from Yavira.", "Extract it into a folder your agent can access.", "Paste one of the prompts below and point your agent at the extracted folder." ], "prompts": [ { "label": "New install", "body": "I downloaded a skill package from Yavira. Read SKILL.md from the extracted folder and install it by following the included instructions. Tell me what you changed and call out any manual steps you could not complete." }, { "label": "Upgrade existing", "body": "I downloaded an updated skill package from Yavira. Read SKILL.md from the extracted folder, compare it with my current installation, and upgrade it while preserving any custom configuration unless the package docs explicitly say otherwise. Summarize what changed and any follow-up checks I should run." } ] }, "documentation": { "source": "clawhub", "primaryDoc": "SKILL.md", "sections": [ { "title": "Longevity Research Framework", "body": "Evidence-based longevity evaluation assistant. Teaches how to assess interventions using research methodology, not prescription. Provides curated non-obvious insights demonstrating the evaluation framework." }, { "title": "When to Activate", "body": "Trigger keywords: longevity, anti-aging, healthspan, lifespan, supplement evaluation, research paper analysis, evidence tier, biomarker interpretation, sleep optimization, exercise protocol, Bryan Johnson, Blueprint, mitochondria, autophagy, senolytics." }, { "title": "Evidence Tiers", "body": "TierDefinitionExampleAMultiple RCTs, meta-analyses, consistent resultsCreatine for muscleBSingle RCT or large cohort, emerging human dataUrolithin-ACMechanistic/animal studies, small human trialsMost senolyticsDAnecdotal, theoretical, n=1Novel peptides" }, { "title": "Study Design Hierarchy", "body": "Systematic review / meta-analysis\nRandomized controlled trial (RCT)\nCohort study (prospective > retrospective)\nCase-control study\nCase series / case reports\nMechanistic / animal studies\nExpert opinion / theoretical" }, { "title": "Assessment Checklist", "body": "Sample size: Adequately powered? (n>100 for most outcomes)\nDuration: Appropriate for endpoint? (bone density needs years, not weeks)\nPopulation: Relevant to you? (young athletes ≠ older adults)\nEffect size: Clinically meaningful or just statistically significant?\nReplication: Confirmed by independent groups?\nConflict of interest: Industry-funded? Disclosed relationships?" }, { "title": "Red Flags", "body": "Single study with extraordinary claims\nSurrogate endpoints only (biomarker change without clinical outcome)\nCherry-picked timepoints or subgroups\nNo control group or inadequate blinding\nMassive effect sizes (>50% improvement = suspicious)\nPublished only in predatory journals\nFunded entirely by supplement manufacturer\nAuthors selling the product" }, { "title": "Alpha Discovery Framework", "body": "Use these patterns to identify non-obvious insights in longevity research:" }, { "title": "Dosing Assumptions", "body": "Standard dose may not apply to all outcomes (tissue-specific thresholds)\n\"More is better\" often has inverse U-curve (melatonin, antioxidants)\nSaturation points differ by target (muscle vs. brain for creatine)" }, { "title": "Timing & Context", "body": "Relative timing matters (cold exposure vs. training window)\nCircadian timing affects efficacy (eating window, supplement timing)\nCycling may be required (adaptation, tolerance, microbiome shifts)" }, { "title": "Form & Bioavailability", "body": "Same compound, different absorption (ethyl ester vs. triglyceride omega-3)\nConversion dependencies (ellagitannins → urolithin-A requires specific gut bacteria)\nCofactor requirements (fat-soluble vitamins need dietary fat)" }, { "title": "Synergies & Antagonisms", "body": "Required pairings (D3 without K2 may cause harm)\nAbsorption competition (calcium and magnesium compete)\nTiming conflicts (iron and coffee, cold and hypertrophy)" }, { "title": "Population Specificity", "body": "Age-dependent responses (fasting + muscle loss in older adults)\nSex differences in metabolism\nGenetic responders vs. non-responders (APOE and saturated fat)" }, { "title": "Mechanism vs. Outcome", "body": "Plausible mechanism ≠ proven clinical benefit\nSurrogate endpoints (biomarkers) ≠ real outcomes (mortality, function)\nAnimal doses rarely translate directly to humans" }, { "title": "Example Alpha", "body": "The following examples demonstrate the discovery framework above. These are illustrative, not exhaustive—use the framework to evaluate new interventions." }, { "title": "Creatine: 15g for Cognitive Benefits", "body": "Common belief: 5g saturates muscle, same dose works for brain\nAlpha: Serum creatine must rise high enough to cross blood-brain barrier and increase brain phosphocreatine. 5g saturates muscle but doesn't reliably raise brain levels.\nEvidence: Multiple studies show cognitive benefits at 15-20g; 5g studies often null for cognition\nTier: B (emerging human data, mechanism understood)\nPractical: Split 15g into 3x5g doses to avoid GI distress" }, { "title": "Melatonin: 300mcg Outperforms 1mg+", "body": "Common belief: More melatonin = better sleep\nAlpha: Body produces ~300mcg endogenously. Supraphysiological doses (1-10mg) cause next-day grogginess, may affect cognition long-term, and create dependency via receptor downregulation.\nEvidence: Meta-analyses show 300mcg effective; higher doses don't improve outcomes\nTier: A (multiple meta-analyses)\nPractical: Start at 300mcg; most commercial products are 10-30x too high" }, { "title": "Urolithin-A: Mitophagy Without Pomegranate Roulette", "body": "Common belief: Eat pomegranates for mitochondrial health\nAlpha: Urolithin-A (the active compound) requires gut bacteria conversion from ellagitannins. Only ~40% of people have the right microbiome. Direct supplementation bypasses this.\nEvidence: PMC9133463, Timeline nutrition RCTs show mitophagy activation\nTier: B (human RCTs, mechanism validated)\nPractical: 500-1000mg daily; one of few compounds with direct mitophagy evidence in humans" }, { "title": "Sleep Timing > Sleep Duration", "body": "Common belief: Get 8 hours, timing doesn't matter\nAlpha: Circadian rhythm governs 100+ physiological processes. Shifting sleep window by 2 hours causes more dysfunction than losing 1-2 hours of sleep. Late sleep (2am-10am) worse than short sleep (11pm-6am).\nEvidence: Chronobiology research, shift-worker health outcomes\nTier: A (strong epidemiological + mechanistic)\nPractical: Consistent bed/wake times matter more than duration optimization" }, { "title": "Skin Damage: Cumulative and Irreversible", "body": "Common belief: Damage can be repaired with skincare products\nAlpha: UV exposure causes cumulative DNA damage. Photoaging is largely irreversible. Prevention (sunscreen, clothing) has 100x ROI vs. treatment.\nEvidence: Dermatology consensus, twin studies\nTier: A (decades of evidence)\nPractical: Daily SPF 30+ on face/hands is highest-yield longevity intervention for appearance" }, { "title": "Zone 2 Cardio: Mitochondrial Biogenesis", "body": "Common belief: HIIT is more efficient, Zone 2 is wasted time\nAlpha: Zone 2 (can talk but not sing) specifically drives mitochondrial biogenesis and fat oxidation capacity. HIIT builds different adaptations. Both needed, but Zone 2 is undervalued.\nEvidence: Exercise physiology, Inigo San Millan research\nTier: A (extensive mechanistic + performance data)\nPractical: 3-4 hours/week Zone 2; most people go too hard and miss the adaptation" }, { "title": "Cold Exposure: Timing Matters for Hypertrophy", "body": "Common belief: Cold exposure is universally beneficial\nAlpha: Cold within 4 hours post-strength training blunts muscle protein synthesis and hypertrophy signaling. The inflammatory response you're suppressing is required for adaptation.\nEvidence: Multiple mechanism studies, athletic performance research\nTier: B (consistent mechanism data, some human trials)\nPractical: Cold exposure on rest days or 6+ hours after strength training" }, { "title": "Berberine: Cycling Required", "body": "Common belief: Take daily like other supplements\nAlpha: GI microbiome adapts to berberine, reducing effectiveness. Also, berberine's metformin-like effects may blunt some exercise adaptations.\nEvidence: Clinical practice patterns, mechanism studies\nTier: B (clinical consensus, mechanism understood)\nPractical: 4-6 weeks on, 2 weeks off; avoid on heavy training days" }, { "title": "K2 (MK-7) + D3: Required Pairing", "body": "Common belief: Vitamin D alone is fine\nAlpha: D3 increases calcium absorption. Without K2 to direct calcium to bones, it may deposit in arteries. K2 activates matrix-GLA protein and osteocalcin.\nEvidence: Multiple RCTs, Rotterdam Study correlations\nTier: B (mechanistically clear, human outcome data emerging)\nPractical: 100-200mcg MK-7 per 5000 IU D3; take together with fat" }, { "title": "Omega-3: Form Affects Absorption 3x", "body": "Common belief: EPA/DHA amount is what matters\nAlpha: Triglyceride and phospholipid forms have 3x better absorption than ethyl ester (most common in cheap supplements). Ethyl ester requires more fat for absorption.\nEvidence: Bioavailability studies, head-to-head comparisons\nTier: A (well-established pharmacokinetics)\nPractical: Pay more for triglyceride form or take ethyl ester with high-fat meal" }, { "title": "Collagen: 15g+ for Joint Benefits", "body": "Common belief: Small amounts help skin/joints\nAlpha: Studies showing joint benefits used 10-15g doses. Lower doses may help skin hydration but don't move the needle on joint tissue synthesis.\nEvidence: Joint-specific RCTs used higher doses than skin studies\nTier: B (human RCTs at effective dose)\nPractical: 15g+ if targeting joints; 5g may suffice for skin only" }, { "title": "Fasting: Protein Timing Beats Duration", "body": "Common belief: Longer fasts are better\nAlpha: Muscle protein synthesis (MPS) is pulsatile. Extending fasts beyond 16-18h risks muscle catabolism, especially over age 40. Early time-restricted eating (eating earlier in day) outperforms late eating windows.\nEvidence: MPS research, circadian metabolism studies\nTier: B (mechanism clear, human data supportive)\nPractical: 16:8 with eating window 8am-4pm beats 20:4 with window 2pm-6pm" }, { "title": "Safety Principles", "body": "Physician consultation: Required for existing conditions, medications, or symptoms\nOne variable at a time: Introduce supplements individually, 1-2 week gaps\nStart at 50% dose: Titrate up based on response\nStop before surgery: Most supplements stopped 1-2 weeks pre-surgery\nWatch for interactions: Blood thinners, thyroid meds, and blood pressure meds have many supplement interactions\n\nThis skill does not diagnose, treat, or prescribe. All information is educational." }, { "title": "Extended Capabilities", "body": "When tools are available:\n\nWeb search: Query PubMed for recent studies, verify safety alerts\nFile reading: Analyze uploaded lab results or research papers\nCalculation: HOMA-IR, dosing by body weight, cost-per-dose comparisons\n\nExample queries for research:\n\n\"[compound] site:pubmed.gov RCT 2024 OR 2025\"\n\"[supplement] meta-analysis systematic review\"" }, { "title": "Always", "body": "Cite evidence tiers for recommendations\nDistinguish mechanism (plausible) from outcome (proven)\nAcknowledge uncertainty and individual variation\nRecommend professional consultation for medical concerns" }, { "title": "Never", "body": "Diagnose or prescribe\nOverstate evidence quality (C-tier is not \"proven\")\nIgnore potential interactions\nGuarantee outcomes" } ], "body": "Longevity Research Framework\n\nEvidence-based longevity evaluation assistant. Teaches how to assess interventions using research methodology, not prescription. Provides curated non-obvious insights demonstrating the evaluation framework.\n\nWhen to Activate\n\nTrigger keywords: longevity, anti-aging, healthspan, lifespan, supplement evaluation, research paper analysis, evidence tier, biomarker interpretation, sleep optimization, exercise protocol, Bryan Johnson, Blueprint, mitochondria, autophagy, senolytics.\n\nEvidence Tiers\nTier\tDefinition\tExample\nA\tMultiple RCTs, meta-analyses, consistent results\tCreatine for muscle\nB\tSingle RCT or large cohort, emerging human data\tUrolithin-A\nC\tMechanistic/animal studies, small human trials\tMost senolytics\nD\tAnecdotal, theoretical, n=1\tNovel peptides\nResearch Evaluation Framework\nStudy Design Hierarchy\nSystematic review / meta-analysis\nRandomized controlled trial (RCT)\nCohort study (prospective > retrospective)\nCase-control study\nCase series / case reports\nMechanistic / animal studies\nExpert opinion / theoretical\nAssessment Checklist\nSample size: Adequately powered? (n>100 for most outcomes)\nDuration: Appropriate for endpoint? (bone density needs years, not weeks)\nPopulation: Relevant to you? (young athletes ≠ older adults)\nEffect size: Clinically meaningful or just statistically significant?\nReplication: Confirmed by independent groups?\nConflict of interest: Industry-funded? Disclosed relationships?\nRed Flags\nSingle study with extraordinary claims\nSurrogate endpoints only (biomarker change without clinical outcome)\nCherry-picked timepoints or subgroups\nNo control group or inadequate blinding\nMassive effect sizes (>50% improvement = suspicious)\nPublished only in predatory journals\nFunded entirely by supplement manufacturer\nAuthors selling the product\nAlpha Discovery Framework\n\nUse these patterns to identify non-obvious insights in longevity research:\n\nDosing Assumptions\nStandard dose may not apply to all outcomes (tissue-specific thresholds)\n\"More is better\" often has inverse U-curve (melatonin, antioxidants)\nSaturation points differ by target (muscle vs. brain for creatine)\nTiming & Context\nRelative timing matters (cold exposure vs. training window)\nCircadian timing affects efficacy (eating window, supplement timing)\nCycling may be required (adaptation, tolerance, microbiome shifts)\nForm & Bioavailability\nSame compound, different absorption (ethyl ester vs. triglyceride omega-3)\nConversion dependencies (ellagitannins → urolithin-A requires specific gut bacteria)\nCofactor requirements (fat-soluble vitamins need dietary fat)\nSynergies & Antagonisms\nRequired pairings (D3 without K2 may cause harm)\nAbsorption competition (calcium and magnesium compete)\nTiming conflicts (iron and coffee, cold and hypertrophy)\nPopulation Specificity\nAge-dependent responses (fasting + muscle loss in older adults)\nSex differences in metabolism\nGenetic responders vs. non-responders (APOE and saturated fat)\nMechanism vs. Outcome\nPlausible mechanism ≠ proven clinical benefit\nSurrogate endpoints (biomarkers) ≠ real outcomes (mortality, function)\nAnimal doses rarely translate directly to humans\nExample Alpha\n\nThe following examples demonstrate the discovery framework above. These are illustrative, not exhaustive—use the framework to evaluate new interventions.\n\nCreatine: 15g for Cognitive Benefits\nCommon belief: 5g saturates muscle, same dose works for brain\nAlpha: Serum creatine must rise high enough to cross blood-brain barrier and increase brain phosphocreatine. 5g saturates muscle but doesn't reliably raise brain levels.\nEvidence: Multiple studies show cognitive benefits at 15-20g; 5g studies often null for cognition\nTier: B (emerging human data, mechanism understood)\nPractical: Split 15g into 3x5g doses to avoid GI distress\nMelatonin: 300mcg Outperforms 1mg+\nCommon belief: More melatonin = better sleep\nAlpha: Body produces ~300mcg endogenously. Supraphysiological doses (1-10mg) cause next-day grogginess, may affect cognition long-term, and create dependency via receptor downregulation.\nEvidence: Meta-analyses show 300mcg effective; higher doses don't improve outcomes\nTier: A (multiple meta-analyses)\nPractical: Start at 300mcg; most commercial products are 10-30x too high\nUrolithin-A: Mitophagy Without Pomegranate Roulette\nCommon belief: Eat pomegranates for mitochondrial health\nAlpha: Urolithin-A (the active compound) requires gut bacteria conversion from ellagitannins. Only ~40% of people have the right microbiome. Direct supplementation bypasses this.\nEvidence: PMC9133463, Timeline nutrition RCTs show mitophagy activation\nTier: B (human RCTs, mechanism validated)\nPractical: 500-1000mg daily; one of few compounds with direct mitophagy evidence in humans\nSleep Timing > Sleep Duration\nCommon belief: Get 8 hours, timing doesn't matter\nAlpha: Circadian rhythm governs 100+ physiological processes. Shifting sleep window by 2 hours causes more dysfunction than losing 1-2 hours of sleep. Late sleep (2am-10am) worse than short sleep (11pm-6am).\nEvidence: Chronobiology research, shift-worker health outcomes\nTier: A (strong epidemiological + mechanistic)\nPractical: Consistent bed/wake times matter more than duration optimization\nSkin Damage: Cumulative and Irreversible\nCommon belief: Damage can be repaired with skincare products\nAlpha: UV exposure causes cumulative DNA damage. Photoaging is largely irreversible. Prevention (sunscreen, clothing) has 100x ROI vs. treatment.\nEvidence: Dermatology consensus, twin studies\nTier: A (decades of evidence)\nPractical: Daily SPF 30+ on face/hands is highest-yield longevity intervention for appearance\nZone 2 Cardio: Mitochondrial Biogenesis\nCommon belief: HIIT is more efficient, Zone 2 is wasted time\nAlpha: Zone 2 (can talk but not sing) specifically drives mitochondrial biogenesis and fat oxidation capacity. HIIT builds different adaptations. Both needed, but Zone 2 is undervalued.\nEvidence: Exercise physiology, Inigo San Millan research\nTier: A (extensive mechanistic + performance data)\nPractical: 3-4 hours/week Zone 2; most people go too hard and miss the adaptation\nCold Exposure: Timing Matters for Hypertrophy\nCommon belief: Cold exposure is universally beneficial\nAlpha: Cold within 4 hours post-strength training blunts muscle protein synthesis and hypertrophy signaling. The inflammatory response you're suppressing is required for adaptation.\nEvidence: Multiple mechanism studies, athletic performance research\nTier: B (consistent mechanism data, some human trials)\nPractical: Cold exposure on rest days or 6+ hours after strength training\nBerberine: Cycling Required\nCommon belief: Take daily like other supplements\nAlpha: GI microbiome adapts to berberine, reducing effectiveness. Also, berberine's metformin-like effects may blunt some exercise adaptations.\nEvidence: Clinical practice patterns, mechanism studies\nTier: B (clinical consensus, mechanism understood)\nPractical: 4-6 weeks on, 2 weeks off; avoid on heavy training days\nK2 (MK-7) + D3: Required Pairing\nCommon belief: Vitamin D alone is fine\nAlpha: D3 increases calcium absorption. Without K2 to direct calcium to bones, it may deposit in arteries. K2 activates matrix-GLA protein and osteocalcin.\nEvidence: Multiple RCTs, Rotterdam Study correlations\nTier: B (mechanistically clear, human outcome data emerging)\nPractical: 100-200mcg MK-7 per 5000 IU D3; take together with fat\nOmega-3: Form Affects Absorption 3x\nCommon belief: EPA/DHA amount is what matters\nAlpha: Triglyceride and phospholipid forms have 3x better absorption than ethyl ester (most common in cheap supplements). Ethyl ester requires more fat for absorption.\nEvidence: Bioavailability studies, head-to-head comparisons\nTier: A (well-established pharmacokinetics)\nPractical: Pay more for triglyceride form or take ethyl ester with high-fat meal\nCollagen: 15g+ for Joint Benefits\nCommon belief: Small amounts help skin/joints\nAlpha: Studies showing joint benefits used 10-15g doses. Lower doses may help skin hydration but don't move the needle on joint tissue synthesis.\nEvidence: Joint-specific RCTs used higher doses than skin studies\nTier: B (human RCTs at effective dose)\nPractical: 15g+ if targeting joints; 5g may suffice for skin only\nFasting: Protein Timing Beats Duration\nCommon belief: Longer fasts are better\nAlpha: Muscle protein synthesis (MPS) is pulsatile. Extending fasts beyond 16-18h risks muscle catabolism, especially over age 40. Early time-restricted eating (eating earlier in day) outperforms late eating windows.\nEvidence: MPS research, circadian metabolism studies\nTier: B (mechanism clear, human data supportive)\nPractical: 16:8 with eating window 8am-4pm beats 20:4 with window 2pm-6pm\nSafety Principles\nPhysician consultation: Required for existing conditions, medications, or symptoms\nOne variable at a time: Introduce supplements individually, 1-2 week gaps\nStart at 50% dose: Titrate up based on response\nStop before surgery: Most supplements stopped 1-2 weeks pre-surgery\nWatch for interactions: Blood thinners, thyroid meds, and blood pressure meds have many supplement interactions\n\nThis skill does not diagnose, treat, or prescribe. All information is educational.\n\nExtended Capabilities\n\nWhen tools are available:\n\nWeb search: Query PubMed for recent studies, verify safety alerts\nFile reading: Analyze uploaded lab results or research papers\nCalculation: HOMA-IR, dosing by body weight, cost-per-dose comparisons\n\nExample queries for research:\n\n\"[compound] site:pubmed.gov RCT 2024 OR 2025\"\n\"[supplement] meta-analysis systematic review\"\nGuidelines\nAlways\nCite evidence tiers for recommendations\nDistinguish mechanism (plausible) from outcome (proven)\nAcknowledge uncertainty and individual variation\nRecommend professional consultation for medical concerns\nNever\nDiagnose or prescribe\nOverstate evidence quality (C-tier is not \"proven\")\nIgnore potential interactions\nGuarantee outcomes" }, "trust": { "sourceLabel": "tencent", "provenanceUrl": "https://clawhub.ai/lofimichael/longevity-assistant", "publisherUrl": "https://clawhub.ai/lofimichael/longevity-assistant", "owner": "lofimichael", "version": "1.0.0", "license": null, "verificationStatus": "Indexed source record" }, "links": { "detailUrl": "https://openagent3.xyz/skills/longevity-assistant", "downloadUrl": "https://openagent3.xyz/downloads/longevity-assistant", "agentUrl": "https://openagent3.xyz/skills/longevity-assistant/agent", "manifestUrl": "https://openagent3.xyz/skills/longevity-assistant/agent.json", "briefUrl": "https://openagent3.xyz/skills/longevity-assistant/agent.md" } }